GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
41.92
+0.29 (+0.70%)
At close: 4:02PM EDT

42.26 +0.34 (0.81%)
Pre-Market: 4:17AM EDT

Stock chart is not supported by your current browser
Previous Close41.63
Open42.00
Bid42.23 x 1100
Ask42.27 x 4000
Day's Range41.85 - 42.04
52 Week Range36.41 - 42.49
Volume3,331,582
Avg. Volume2,279,964
Market Cap104.431B
Beta (3Y Monthly)0.52
PE Ratio (TTM)42.26
EPS (TTM)0.99
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield1.86 (4.43%)
Ex-Dividend Date2019-08-08
1y Target Est45.92
Trade prices are not sourced from all markets
  • Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids
    Zacks

    Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids

    Glaxo's (GSK) SLE drug Benlysta gets a favorable CHMP opinion that recommends an approval for intravenous formulation in pediatric patients.

  • Merck's Two HIV Drugs Get FDA Approval for Expanded Use
    Zacks

    Merck's Two HIV Drugs Get FDA Approval for Expanded Use

    Merck's (MRK) new HIV drugs, Pifeltro and Delstrigo, get FDA nod for use in treatment-experienced adults living with HIV-1 who are virologically suppressed.

  • Benzinga

    The Week Ahead In Biotech: Spotlight On ESMO Conference

    Biotech stocks put up a muted performance in the week ended Sept. 20 amid conference presentations and FDA approvals. Johnson & Johnson (NYSE: JNJ )'s Janssen unit received an FDA nod for label expansion ...

  • Beyond Meat snags Tesla exec, Microsoft shakes up board, Larry Ellison blasts Uber & WeWork
    Yahoo Finance

    Beyond Meat snags Tesla exec, Microsoft shakes up board, Larry Ellison blasts Uber & WeWork

    Beyond Meat, Tesla, Google, Microsoft and Uber are the companies to watch.

  • Reuters

    Microsoft nominates GSK CEO Walmsley to board

    Microsoft Corp said on Thursday it has nominated GlaxoSmithKline Plc Chief Executive Officer Emma Walmsley to its board of directors. The software company said former chairman of the board of management at BMW AG, Helmut Panke, will not seek a re-election to the board after his current term expires. Charles Noski, former vice chairman of AT&T Inc and Bank of America Corp, is also leaving the board.

  • MarketWatch

    Microsoft adds GlaxoSmithKline CEO to board, among other changes

    Microsoft Corp. said late Thursday that it had nominated the Chief Executive of GlaxoSmithKline to the company's board of directors and that two long-serving board members are resigning. The board nominee, Emma Walmsley, has served as GlaxoSmithKline CEO sine 2017 and has been on the executive team since 2011. Microsoft said Charles Noski and Helmut Panke were resigning. The company's annual shareholder meeting is Dec. 4, when shareholders will vote on the nominee. Microsoft stock was down 0.2% in the extended session and closed up 1.8% to $141.07 Thursday. The S&P 500 index was flat in Thursday trading.

  • InvestorPlace

    5 Undervalued Stocks to Buy

    [Editor's note: This story was previously published in February 2019. It has since been updated and republished.]Overall, the stock market continued its huge improvement throughout 2019, compared to where it ended in 2018; it has been a complete turnaround from last year's drop, when stocks entered bear-market territory. Markets started slipping again in the month of August, traded in a range, and then turned to rally to new all-time highs.But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have done so well. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy; it has just become a little trickier to find them amid all the flashy comeback stories.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo find the best stocks to buy now, disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the back burner for later. Among such stocks, companies that got left out of the rally are the most compelling. Even better, some of the best undervalued stocks to buy are those that dropped by double-digit percentages during the current rally.Why is that?Stocks that have already priced in current and possible negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower. * 8 Dividend Stocks to Buy for a Recession With all of that in mind, here are five undervalued stocks to buy that aren't as scary as they seem. Sony (SNE)Investors who held Sony (NYSE:SNE) stock through the Q2 2019 earnings report posted on July 30 enjoyed the rally that followed. The stock rose from $54.50 to nearly $60 recently. The company reported revenue falling just 1.4% year-over-year but operating income rose 18%, up 35.9 billion yen (US $332.2 million).Now that Sony is trading at yearly highs, investors need not sell the stock just yet.Why not?In a Sept 13 report, video game sales in August fell again by 18%, to $666 million. The industry could not count on any big game title hits to lift monthly sales. But the gaming sector has some hope ahead. When Sony's Playstation 5 arrives, SNE will have more power than ever. Though the PS5 release will release no sooner than mid-2020, 8K support and game refreshes should give Sony another boost in revenue when the time comes.Sony faced a few headwinds in the quarter. Contributions from first-party software titles fell. Sales of non-first party titles declined. But PS4 hardware sales rose, as did network service sales, including sales of PlayStation Plus. Celestica (CLS)In July, Celestica (NYSE:CLS) reported weak Q2/2019 results that sent the stock to as low as $6 by the end of August. Celestica reported revenue of $1.45 billion, down 15% from last year. Its aerospace and defense segment etched out a 2% revenue growth in the period, offset by a 23% decline in revenue from its Connectivity and Cloud Solutions (CCS) division. Adjusted EPS was $0.12, down from $0.29 last year. In September, the stock staged a major rally.The company supplies equipment in ATS -- aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line.Celestica stock is still an undervalued play worth considering. The stock may underperform a while longer and risks disappointing investors. Again. Consider watching the stock's next earnings report before committing to a position. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Celestica stock is an undervalued stock worth considering. AbbVie (ABBV)Back when I first wrote this list of undervalued stocks, Allergan (NYSE:AGN) was the pick in this slot. And it paid off. Investors buying Allergan at the start of 2019 may have made up to $50 a share, peak to trough. In June, the stock fell below $115, only to peak at around $165 in July when my new pick, AbbVie (NYSE:ABBV), agreed to buy out the firm for $63 billion. AbbVie's rationale for acquiring Allergan is two-fold.First, it views Allergan's portfolio of products, including Botox, as attractive. Second, it has the time to use the strong cash flow from Humana to pay off its Allergan acquisition. Once Humana faces fierce competition from generics, AbbVie will have paid off much of the debt related to the AGN buyout. And in a few years time, Allergan's drugs in the development pipeline will be ready for market.AbbVie's long-term future planning through the AGN acquisition makes AbbVie stock appealing for dividend-income investors. Even though shares rose from a $62.66 52-week low to $71.55, the stock still pays a dividend that yields 6%.At a Sep. 10 Healthcare Conference, AbbVie reiterated its commitment to cut debt and to continue growing its dividend. It will also allocate some cash for smaller mid- to late-state pipeline opportunities. Management has a good handle on integrating Allergan into its business but it will not let its existing pipeline suffer in any way.ABBV trades at an ~10% discount to the analyst price target of $79, but I think the AGN acquisition brings ABBV far more upside than that. Innoviva (INVA)Innoviva (NASDAQ:INVA) is another stock in the drug space whose large drop starting in late January continued throughout 2019. The stock may not yet be done falling. Why not?The fell began when the FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo.Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to buy now.Innoviva shares trended lower throughout 2019, as the stock lost $3 on its stock price by late-July. Investors sold the stock following the company's weak Q2 report. Innoviva reported Glaxo (NYSE:GSK) royalties falling 18% to $313.9 million. Overall, there was a net income decline of 31% (an EPS of $0.34).In its press release, the company said:"Management and the board continue to examine potential strategic actions to maximize future shareholder value." * 7 Momentum Stocks to Buy On the Dip Innoviva incurred expenses related to the evaluation of strategic options. But it will need to deliver on better shareholder value to attract stock buyers. Vodafone (VOD)Telecom stocks were out of favor heading into 2019. Now, telecom stocks are no longer out of favor. But Vodafone (NASDAQ:VOD), which after cratering in May, has just barely climbed back to it's pre-Christmas levels. So VOD is definitely still an undervalued stock.On July 26, Vodafone reported revenue stabilizing, falling just 2.3% Y/Y. The results sent VOD stock up 9% on the day. And ever since the stock bottomed at $16, it continues to run higher, closing recently at close to $20. In the fiscal Q1 2020 report, Vodafone said it enjoyed record low mobile contract churn. The deepening customer engagement will only strengthen as the telecom company launches 5G in all major EU markets.Service revenue in Q1 was mostly flat, down 0.2% and 0.5 pp sequentially.Simplifying the mobile plan offering will likely lead to higher revenue growth ahead. For example, Vodafone migrated 500,000 SIMs to a new unlimited offer. This will also increase ARPU and keep customers from switching to competitor services.Vodafone shares pay a dividend yield of 5.2%. If Vodafone grows its U.K. business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva and AbbVie.The post 5 Undervalued Stocks to Buy appeared first on InvestorPlace.

  • GSK's over-the-counter nicotine oral spray gets FDA panel backing
    Reuters

    GSK's over-the-counter nicotine oral spray gets FDA panel backing

    The panel voted 9-6 in favour of the therapy, saying its benefits as a smoking cessation aid outweighed risks. The FDA usually follows the recommendations of its experts, but is not mandated to do so. The dose of nicotine is gradually reduced and then discontinued over a 12-week period, allowing the person to break out of the habit of smoking.

  • Reuters

    UPDATE 1-GSK's over-the-counter nicotine oral spray gets FDA panel backing

    An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc's over-the-counter nicotine oral spray that aims to help smokers quit their addiction. The panel voted 9-6 in favor of the therapy, saying its benefits as a smoking cessation aid outweighed risks. The FDA usually follows the recommendations of its experts, but is not mandated to do so.

  • Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis
    Zacks

    Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis

    Roche's (RHHBY) lymphoma drug, Gazyva, obtains Breakthrough Therapy designation in the United States for lupus nephritis.

  • Here's Why GlaxoSmithKline (LON:GSK) Can Manage Its Debt Responsibly
    Simply Wall St.

    Here's Why GlaxoSmithKline (LON:GSK) Can Manage Its Debt Responsibly

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use
    Zacks

    Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use

    Glaxo's (GSK) asthma medicine, Nucala gets FDA approval for use in pediatric patient population.

  • Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others
    Zacks

    Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others

    Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.

  • Business Wire

    Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma

    GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma. Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the US. Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: “Children with severe eosinophilic asthma currently have limited treatment choices available to them.

  • Leaner Pfizer Positioned to Boost R&D Output
    GuruFocus.com

    Leaner Pfizer Positioned to Boost R&D Output

    Company’s recent decisions will enable it to concentrate on building core business Continue reading...

  • Reuters

    Factbox: Purdue OxyContin settlement would rank among largest in pharma history

    The settlement could be valued at up to $12 billion, they said, which would make it the largest such settlement in U.S. pharmaceutical history. The following are some of the largest previous U.S. legal settlements involving the pharmaceutical industry. * Merck & Co $4.85 billion, 2007 - Three years after it pulled its widely used arthritis pain drug Vioxx from the market over safety concerns and following several product liability trials, Merck agreed to pay nearly $5 billion to settle most of the 60,000 lawsuits alleging that Vioxx caused heart attacks and strokes.

  • Generic Drug Stocks Latch Onto Buyout News — Leading To 3-Day Rally
    Investor's Business Daily

    Generic Drug Stocks Latch Onto Buyout News — Leading To 3-Day Rally

    Shares of generic pharmaceutical companies rallied Friday after Perrigo announced its acquisition of GlaxoSmithKline's heartburn treatment, a medicine known as Prevacid 24-hour.

  • Pfizer is a Top Drugmaker: Is it the Right Time to Buy It?
    Zacks

    Pfizer is a Top Drugmaker: Is it the Right Time to Buy It?

    Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales of key drugs Prevnar and Xeljanz.

  • Trying to turn 'natural killers' against cancer, Peninsula drug maker raises $114 million
    American City Business Journals

    Trying to turn 'natural killers' against cancer, Peninsula drug maker raises $114 million

    Aiming to use so-called "natural killer" cells to rev up the immune system against cancer, Nkarta Therapeutics Inc. raised $114 million from a lineup of biotech and crossover investors that hints at an IPO. The South San Francisco company, headed by biotech industry leader Paul Hastings, plans to enter clinical trials with two types of engineered natural killer cells, part of the body's innate immune system that forms a frontline defense against foreign invaders.

  • 3 International Stocks Worth Watching
    Motley Fool

    3 International Stocks Worth Watching

    It pays to diversify your portfolio.

  • Here's Why Glaxo (GSK) Steadily Stays Ahead of Its Industry
    Zacks

    Here's Why Glaxo (GSK) Steadily Stays Ahead of Its Industry

    Shares of Glaxo (GSK) surpass the industry this year. Here are some reasons for the same.

  • AstraZeneca's Lupus Drug Meets Primary Endpoint in Study
    Zacks

    AstraZeneca's Lupus Drug Meets Primary Endpoint in Study

    AstraZeneca's (AZN) second phase III study evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus meets the primary endpoint.

  • Forget Pfizer, Add These Big Drugmakers to Your Portfolio
    Zacks

    Forget Pfizer, Add These Big Drugmakers to Your Portfolio

    Buy these three large drug companies instead of Pfizer (PFE) as the stock is down this year.

  • Emergent's Vaccine Portfolio Aids Growth Amid Competition
    Zacks

    Emergent's Vaccine Portfolio Aids Growth Amid Competition

    Emergent's (EBS) vaccine portfolio holds potential with the newly-acquired Narcan nasal spray performing well in the first half of 2019. Stiff competition is a lingering concern.

  • Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo
    Zacks

    Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo

    Ionis (IONS) out-licenses antisense medicines to Glaxo for treating chronic hepatitis B virus infection. Glaxo exercises its option to in-license the same. Shares fall.